Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 15/20 | 1.00 |
| ▸ | ADAM17 | P78536 | 12/20 | 1.00 |
| ▸ | MMP3 | P08254 | 10/20 | 1.00 |
| ▸ | MMP2 | P08253 | 10/20 | 1.00 |
| ▸ | MMP9 | P14780 | 10/20 | 1.00 |
| ▸ | MMP7 | P09237 | 8/20 | 1.00 |
| ▸ | MMP8 | P22894 | 6/20 | 1.00 |
| ▸ | MMP14 | P50281 | 2/20 | 1.00 |
| ▸ | ADAM10 | O14672 | 2/20 | 0.65 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prinomastat SCHEMBL3955053 | 1.00 | MMP1 (1.00) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL115696 | 1.00 | MMP1 (1.00) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL7765017 | 0.99 | MMP1 (0.98) | MMP1MMP13ADAM17MMP3MMP2 | |
| Prinomastat SCHEMBL6810941 | 0.99 | MMP1 (0.98) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL12272301 | 0.92 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6432297 | 0.90 | MMP1 (0.81) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6336108 | 0.90 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6432301 | 0.90 | MMP1 (0.81) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL3912779 | 0.90 | MMP1 (0.85) | MMP1MMP13ADAM17MMP3MMP2 | |
| SCHEMBL6344484 | 0.89 | MMP1 (0.83) | MMP1MMP13ADAM17MMP3MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | claimed |
| WO-1998047494-A2 | NOVEL USE OF MATRIX METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-10-29 | — | — | WO | claimed |
| WO-2020252439-A1 | CARBORANE HYDROXAMIC ACID MATRIX METALLOPROTEINASE AGENTS FOR BORON NEUTRON CAPTURE THERAPY | LOYOLA UNIVERSITY OF CHICAGO (US) | 2020-12-17 | — | — | WO | disclosed |
| CN-104174071-A | COMPOSITIONS AND SYSTEMS FOR FORMING CROSSLINKED BIOMATERIALS AND ASSOCIATED METHODS OF PREPARATION AND USE | ANGIODEVICE INTERNAT GMBH | 2014-12-03 | — | — | CN | disclosed |
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | AGOURON PHARMACEUTICALS, INC. | 2004-11-18 | — | — | US | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |
| WO-1998047494-A2 | NOVEL USE OF MATRIX METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229817-A1 | Inhibitors of Hepatitis C virus, compositions and treatments using the same | TIMP3, MMP2, MMP7 | MMP1 10/4885MMP13 6/4885ADAM17 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.